Aranesp® (darbepoetin alfa) administered once every 2 weeks (Q2W) maintains recommended haemoglobin (hb) in chronic kidney disease (ckd) patients on haemodialysis switched from weekly (QW) dosing

被引：0

作者：

Carrera, Fernando ^{[1
]}

Oliveira, Lino ^{[1
]}

Maia, Pedro ^{[1
]}

Mendes, Teresa ^{[1
]}

Ferreira, Candido ^{[1
]}

机构：

[1] Eurodial, Dialysis Unit, Leiria, Portugal

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2006年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

引用

页码：148 / 149

页数：2

共 50 条

[31] The effect of every-other-week (Q2W) darbepoetin alfa on hemoglobin (HB) levels and health-related quality of life (HRQOL) in older chronic kidney disease (CKD) patients naive to recombinant human erythropoietin (RHUEPO).
Abu-Alfa, A
Hertel, J
Locay, H
Scarlata, D
Globe, D
Audhya, P
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2006, 54 (04) : S71 - S71
[32] Every-2-week (Q2W) dosing of darbepoetin alfa in patients with anemia of cancer (AOC): Interim analysis of a randomized, controlled study.
Charu, V
Belani, CP
Gill, AN
Bhatt, M
Ben-Jacob, A
Tomita, D
Katz, D
Colowick, A
BLOOD, 2003, 102 (11) : 499A - 499A
[33] Baseline (BL) covariates of response to darbepoetin alfa (DA) every 2 weeks (Q2W) in patients (pts) with chemotherapy-induced anemia (CIA).
Vadhan-Raj, S
Mirtsching, B
Gregory, SA
Hong, J
Fessen, M
Yao, B
Rossi, G
Blayney, D
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 744S - 744S
[34] Study design and baseline patient (PT) characteristics from the alternate study:: A long-term non-interventional trial to evaluate the effectiveness of aranesp® (darbepoetin alfa; DA) in dialysis pts when administered once every two weeks (Q2W)
De Meester, J.
Feriani, M.
McMahon, L.
Pronai, W.
Simon, P.
Merrell, E.
Walsh, C.
Molemans, B.
Rottembourg, J.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 343 - 344
[35] Initial experience with darbepoetin alta administered at a fixed dose of 200 mcg every 2 weeks (Q2W) in anemic cancer patients undergoing chemotherapy
Thames, W
Dozier, N
Alley, JL
Yao, B
Kerr, RO
BLOOD, 2002, 100 (11) : 18B - 18B
[36] Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) versus epoetin alfa 40,000 U weekly (QW) in patients with chemotherapy-induced anemia (CIA)
Glaspy, J
Berg, R
Tomita, D
Rossi, G
Vadhan-Raj, S
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 760S - 760S
[37] Maintenance dosing with epoetin alfa every two weeks (Q2W) in anemic patients with cancer receiving chemotherapy every one or four weeks: Final results.
Gregory, SA
Xie, J
Woodman, RC
BLOOD, 2005, 106 (11) : 21B - 21B
[38] De novo every-other-week (Q2W) darbepoetin alfa used to correct hemoglobin (Hb) levels in older chronic kidney disease (CKD) subjects nalive to erythropoiesis-stimulating protein (ESP) treatment.
Krause, M.
Agarwal, A.
Silver, M.
Lei, L.
Klassen, P.
Kewalramani, R.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (04) : S77 - S77
[39] Weekly epoetin alfa (QW) provides similar hematologic outcomes to front-loading (FL) darbepoetin alfa regimens and better outcomes compared to darbepoetin alfa (Q2W) in patients with chemotherapy-related anemia.
Duh, MS
Lefebvre, P
Dector, AJ
Watson, SH
McKenzie, SR
Piech, CT
BLOOD, 2003, 102 (11) : 511B - 512B
[40] Every-two-week (Q2W) maintenance dosing with epoetin alfa in anemic patients with cancer receiving chemotherapy: 60,000 U QW to target Hb 12 g/dL, followed by 60,000 U Q2W
Gregory, SA
Baltz, B
Williams, D
BLOOD, 2004, 104 (11) : 144B - 144B

← 1 2 3 4 5 →